Once-daily dosing can substantially reduce a patient’s pill burden4


ALUNBRIG® (brigatinib) offers 1 tablet, once-daily dosing, or 365 pills per year4

Small orange pill bottle with white pills.

up to 365 tablets / capsules a yeara

Medium orange pill bottle with while pills.

up to 730 tablets / capsules a yeara

Large orange pill bottle filled with white pills.

up to 2,920 tablets / capsules a yeara

aRecommended dose.

Download the ALUNBRIG Dosing Guide

Learn More About the Benefits of Once-Daily Dosing

Category 1, Preferred NCCN Recommendation.

National Comprehensive Cancer Network® (NCCN®): recommends brigatinib as a Category 1, preferred first-line treatment option for ALK+ metastatic NSCLC5,b,c,d

Which of these other considerations is a top priority for you?

Step 1 of 2

Connect with our team to learn more about how ALUNBRIG® (brigatinib) may be right for your patient

bWhen an ALK rearrangement is discovered prior to first-line systemic therapy.5
cThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
®) for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories.
dSee the NCCN Guidelines
® for detailed recommendations, including other preferred treatment options.

ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; mNSCLC, metastatic NSCLC; NSCLC, non-small cell lung cancer.